Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Non-Current Debt (2016 - 2025)

Guided Therapeutics' Non-Current Debt history spans 12 years, with the latest figure at $29000.0 for Q3 2025.

  • For Q3 2025, Non-Current Debt fell 45.28% year-over-year to $29000.0; the TTM value through Sep 2025 reached $29000.0, down 45.28%, while the annual FY2024 figure was $47000.0, N/A changed from the prior year.
  • Non-Current Debt for Q3 2025 was $29000.0 at Guided Therapeutics, down from $35000.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $592000.0 in Q4 2021 and bottomed at $6000.0 in Q1 2021.
  • The 4-year median for Non-Current Debt is $59000.0 (2024), against an average of $213846.2.
  • The largest annual shift saw Non-Current Debt crashed 98.96% in 2021 before it skyrocketed 9366.67% in 2022.
  • A 4-year view of Non-Current Debt shows it stood at $592000.0 in 2021, then plummeted by 85.98% to $83000.0 in 2022, then plummeted by 43.37% to $47000.0 in 2024, then tumbled by 38.3% to $29000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Non-Current Debt are $29000.0 (Q3 2025), $35000.0 (Q2 2025), and $41000.0 (Q1 2025).